NASDAQ$SCPX
Scorpius Holdings Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
NightHawk Biosciences reported an increase in revenue from process development and a net loss for Q2 2023.
NightHawk Biosciences reported $0.7 million in revenue from process development, an increase compared to the previous year. The company's net loss was $13.9 million, or $0.53 per share. The company had $18.6 million in cash, cash equivalents, and short-term investments as of June 30, 2023.
- Revenue from process development increased due to the San Antonio CDMO facility operations.
- Research and development expenses increased by 21.3% due to HS-110 expense, ANTHIM, and unallocated research expenses.
- Cost of revenues were $0.4 million, reflecting direct costs of labor, overhead, and materials.
- Net loss was $13.9 million, or $0.53 per share, compared to $6.8 million, or $0.27 per share in the prior year.
Headline financials
Revenue & EPS history
Scorpius Holdings · Revenue · Quarterly
$658K
Revenue by segment
Scorpius Holdings · $459K total across 1 segment · Q2 2021
- Grant and Contract Revenue$459K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.3%
Avg return
Earnings day
+100.8%
Avg return
5 days after
+129.2%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+5.2%
Q1 2021
Best reaction
-9.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +1350.0% | +3100.0% | |
| Q2 2025 | +0.0% | +900.0% | -60.0% | |
| Q1 2025 | -1.4% | +0.7% | +4.1% | |
| Q4 2024 | +0.0% | -1.5% | -2.9% | |
| Q1 2026 | +2.8% | -41.4% | -41.1% | |
| Q1 2024 | +2.8% | -41.4% | -41.1% | |
| Q3 2024 | +3.5% | +12.6% | -35.6% | |
| Q4 2023 | +0.0% | +2.1% | -19.1% | |
| Q3 2023 | -0.8% | -13.7% | -34.5% | |
| Q2 2023 | -1.6% | -12.9% | -2.9% | |
| Q1 2023 | -0.0% | -4.0% | -24.6% | |
| Q4 2022 | -0.0% | -4.0% | -24.6% | |
| Q3 2022 | +2.3% | -4.4% | -33.6% | |
| Q2 2022 | +0.4% | -11.5% | -22.2% | |
| Q1 2022 | -1.0% | -5.8% | -23.3% | |
| Q4 2021 | -9.4% | +12.4% | +17.9% | |
| Q3 2021 | -2.5% | -7.2% | -21.6% | |
| Q2 2021 | +1.2% | -4.3% | -4.1% | |
| Q1 2021 | +5.2% | +6.2% | -0.7% | |
| Q4 2020 | +1.8% | -8.9% | -10.3% | |
| Q3 2020 | -9.6% | -7.0% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro